Compared to TNF inhibitors, IL-23 inhibitors showed a significantly smaller risk of certain malignancies through five-year follow-up time, including non-Hodgkin lymphoma (0.8 vs. 0.2%), hepatobiliary cancer (3.3% vs. 0.7%), and basal cell cancer (3.3% vs. 1.4%). Here, IL23A is linked to basal cell carcinoma.